Chemotherapy Response Monitoring With 18F-choline PET/CT in Hormone Refractory Prostate Cancer

Status: Completed

Location: See location...

Intervention Type: Drug

Study Type: Interventional

Study Phase: Phase 1/Phase 2

SUMMARY

The purpose of this study is to determine whether imaging with 18F-choline PET/CT can provide information that may help guide subsequent investigational or clinical treatments for patients with advanced (hormone-refractory) metastatic prostate cancer.

Eligibility

Participation Requirements

Sex: Male

Minimum Age: 18

Healthy Volunteers: No

View:

• Provision of written informed consent.

• Men, over 18 years of age, with histologically-confirmed diagnosis of prostate cancer

• History of treatment by complete androgen blockade for greater than 3 months prior to enrollment

• Progressive disease evidenced by 2 consecutive rises in PSA measured at least 1 week apart, with the absolute value of the latest PSA > 5.0 ng/ml.

• A rise in PSA following anti-androgen drug withdrawal, above the last PSA value before withdrawal.

• Patient has agreed to treatment for hormone-refractory (ie. castrate-resistant) prostate cancer under supervision of a medical oncologist, urologist, radiation oncologist or nuclear medicine physician. Treatments indicated for HRPC are docetaxel-, cabazitaxel-, or mitoxantrone-based chemotherapy, abiraterone, radium-223, enzalutamide, or sipulecuil-T.

Locations

United States

Hawaii

The Queen's Medical Center

Honolulu

Time Frame

Start Date: June 2009

Completion Date: June 2016

Participants

Target number of participants: 25

Treatments

Experimental: Received 18F-fluorocholine PET/CT

IV fluorine-18 labeled methylcholine before PET/CT

Authors

Sandi A Kwee

Related Therapeutic Areas

Prostate Cancer

Chemotherapy Response Monitoring With 18F-choline PET/CT in Hormone Refractory Prostate Cancer

Similar Clinical Trials

A Phase 1/2, Open-label, Multicenter, Dose Escalation and Dose Expansion Study of SAR442720 in Combination With Other Agents in Participants With Advanced Malignancies

A Phase III, Multicenter, Prospective, Randomized, Patients With Resectable Pancreatic Cancer With Elevated Serum CA125 Were Compared With Those Who Did Not Receive Neoadjuvant Chemotherapy.

Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)